Cargando…

732. Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism

BACKGROUND: Posaconazole is an extended-spectrum triazole used in the treatment and prophylaxis of many fungal diseases. There have been case reports of posaconazole-induced pseudohyperaldosteronism; however, its occurrence and association with serum posaconazole drug levels need further investigati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Minh-Vu Hoang, Davis, Matthew R, Wittenberg, Rebecca, Mchardy, Ian, Baddley, John W, Young, Brian, Odermatt, Alex, Thompson, George R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810883/ http://dx.doi.org/10.1093/ofid/ofz360.800

Ejemplares similares

752. Management of 20 Patients Diagnosed with Posaconazole-Induced Pseudohyperaldosteronism
por: Gintjee, Thomas J, et al.
Publicado: (2020)

Posaconazole-Induced Hypertension and Hypokalemia: Mechanistic Evaluation
por: Thompson, George R, et al.
Publicado: (2017)

Severe Posaconazole-Induced Glucocorticoid Deficiency with Concurrent Pseudohyperaldosteronism: An Unfortunate Two-for-One Special
por: Villar-Prados, Alejandro, et al.
Publicado: (2021)

ODP442 Posaconazole-induced Pseudohyperaldosteronism (PIPH) in Patient Treated for Acute Myeloid Leukemia
por: Shrestha, Bishow, et al.
Publicado: (2022)

Gynecomastia and hypertension in a patient treated with posaconazole
por: Thompson, George R., et al.
Publicado: (2020)

Licorice: From Pseudohyperaldosteronism to Therapeutic Uses
por: Sabbadin, Chiara, et al.
Publicado: (2019)

Licorice induced pseudohyperaldosteronism, severe hypertension, and long QT
por: Smedegaard, Stine Bech, et al.
Publicado: (2019)

Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
por: Thompson, George R, et al.
Publicado: (2019)

732. Description of Diagnoses and Antibiotic Management of Otitis Media and Otitis Externa in Adults
por: Pontefract, Benjamin, et al.
Publicado: (2018)

A Case of Pseudohyperaldosteronism Induced by Yokukansan and Shakuyakukanzoto That Resulted in Severe Hypokalemia
por: Arai, Mika, et al.
Publicado: (2023)

974. Real World Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels
por: Pasikhova, Yanina, et al.
Publicado: (2023)

411. Tolerability of Isavuconazole After Posaconazole Toxicity in Leukemia Patients
por: DiPippo, Adam J, et al.
Publicado: (2018)

Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center
por: Haidar, Ghady, et al.
Publicado: (2017)

732 Predictors of Cardiac Implantable Electronic Device Infection in Patients with Staphylococcus Aureus Bacteremia
por: Elmalik, Hassan, et al.
Publicado: (2014)

732. Increase in the Proportion of Hospitalizations in the Setting of Methicillin-Susceptible vs. Resistant Staphylococcus aureus in New York City (NYC)
por: Bromberg, Maria, et al.
Publicado: (2023)

732 Economic and Environmental Benefits of Telemedicine Expansion
por: Miotke, Sam, et al.
Publicado: (2023)

732. Evaulation of Micafungin Treatment at Pediatric Patients: A cross-sectional Study from Tertiary Pediatric Centre
por: Arıkan, Kamile, et al.
Publicado: (2020)

2571. Posaconazole DRT in Children; Time to Bring Out the Pill Crusher?
por: Weerdenburg, Heather L, et al.
Publicado: (2023)

CCNP Wireless 642-732 CUWSS quick reference
por: Henry, Jerome
Publicado: (2012)

PT732. Successful treatment with a combination of thyrotropin-releasing hormone (TRH) and hyperbaric oxygen (HBO) for an interval form of carbon monoxide (CO) poisoning
por: Omori, Waturu, et al.
Publicado: (2016)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

How Much Is Too Much? Exploring Pseudohyperaldosteronism in Glycyrrhizic Acid Toxicity From Chronic Licorice Root Consumption
por: Patel, Palak, et al.
Publicado: (2021)

Identification of an Alternative Glycyrrhizin Metabolite Causing Liquorice-Induced Pseudohyperaldosteronism and the Development of ELISA System to Detect the Predictive Biomarker
por: Ishiuchi, Kan'ichiro, et al.
Publicado: (2021)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia
por: Winchell, Gregory A, et al.
Publicado: (2019)

Corrigendum: Identification of an alternative glycyrrhizin metabolite causing liquorice-induced pseudohyperaldosteronism and the development of ELISA system to detect the predictive biomarker
por: Ishiuchi, Kan’ichiro, et al.
Publicado: (2022)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Panniculectomy Outcomes by Body Mass Index: an Analysis of 12,732 Cases
por: Cadwell, Joshua B., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
por: Castanheira, Mariana, et al.
Publicado: (2020)

732. Sensitivity and Specificity of Point of Care Lung Ultrasound vs. Chest X-Ray for the Diagnosis of Pediatric Pneumonia in Limited resource settings: The Zambia Experience
por: Camelo, Ingrid Y, et al.
Publicado: (2021)

388. New Observations in Coccidioidomycosis Serology
por: Mchardy, Ian, et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

1700. Posaconazole-Induced Excess Mineralocorticoid Syndrome with Hypertension, Hypokalemia, and Inhibition of 11-b-hydroxylase in Pediatric Patients
por: Chen, Tempe K, et al.
Publicado: (2023)

A NEW MARAGLAS, D.E.R.® 732, EMBEDMENT FOR ELECTRON MICROSCOPY
por: Erlandson, Robert A.
Publicado: (1964)

Role of posaconazole in the treatment of oropharyngeal candidiasis
por: Ianas, Voichita, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tuiufdnuvudsnig8sg0esk2d6s